Brief: vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold

vTv Therapeutics

26/07/2024 23:33

July 26 (Reuters) - vTv Therapeutics Inc  VTVT.O :
    * VTV THERAPEUTICS ANNOUNCES CADISEGLIATIN PROGRAM FOR TYPE
1
DIABETES PLACED ON CLINICAL HOLD
    * VTV THERAPEUTICS INC - CADISEGLIATIN HAS BEEN
WELL-TOLERATED IN
OVER 500 SUBJECTS TO DATE WITH UP TO SIX MONTHS OF TREATMENT
    * VTV THERAPEUTICS INC - CLINICAL HOLD INCLUDES ONGOING
CATT1
PHASE 3 TRIAL
    * VTV: CLINICAL HOLD BASED ON CHROMATOGRAPHIC SIGNAL IN
RECENT
HUMAN ADME STUDY OF CADISEGLIATIN COULD NOT BE RESOLVED BY
STANDARD MASS SPECTROSCOPY
    * VTV THERAPEUTICS INC: AGENCY REQUIRES A SINGLE IN VITRO
STUDY TO
CHARACTERIZE SIGNAL BEFORE CADISEGLIATIN PROGRAM CAN RESUME

Source text for Eikon:  ID:nGNX4Z4pds 
Further company coverage:  VTVT.O 

 ((reuters.briefs@thomsonreuters.com;))